Melanoma News and Research

Latest Melanoma News and Research

Dartmouth investigators create fast-track research tool to study mouse melanoma cell lines

Dartmouth investigators create fast-track research tool to study mouse melanoma cell lines

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

Researchers identify mutations that destabilize DNA structure that turns a gene off

Researchers identify mutations that destabilize DNA structure that turns a gene off

Pivotal trial of Elios melanoma vaccine to be conducted at top U.S. cancer hospitals

Pivotal trial of Elios melanoma vaccine to be conducted at top U.S. cancer hospitals

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Penn study has implications for developing new cell-based treatments for skin disease

Penn study has implications for developing new cell-based treatments for skin disease

Andor's Komet software used to automatically score modified 3D 'Comet' assay results

Andor's Komet software used to automatically score modified 3D 'Comet' assay results

New technique allows rapid, large-scale studies of gene function

New technique allows rapid, large-scale studies of gene function

Myriad Genetics highlights three new studies at SABCS 2014

Myriad Genetics highlights three new studies at SABCS 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

UT Southwestern biophysicist named recipient of 2015 Edith and Peter O'Donnell Award in Science

UT Southwestern biophysicist named recipient of 2015 Edith and Peter O'Donnell Award in Science

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Baylor-led researchers identify gene linked to familial glioma

Baylor-led researchers identify gene linked to familial glioma

Nivolumab drug highly effective for Hodgkin's lymphoma

Nivolumab drug highly effective for Hodgkin's lymphoma

Novel treatments show promising results in patients with different hematologic disorders

Novel treatments show promising results in patients with different hematologic disorders

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.